ONC

Beone Medicines Stock Analysis

AI Rating

Neutral
  • Quality5/10
  • Growth↑ 8/10
  • Value↓ 1/10
Beone Medicines sales and earnings growth
ONC Growth
Good
  • Revenue Y/Y↑ 40.23%
  • EPS Y/Y↑ 142.55%
  • FCF Y/Y↑ 248.71%
Beone Medicines gross and profit margin trends
ONC Profitability
Good
  • Gross margin ↑ 87.50%
  • EPS margin↓ 5.40%
  • ROIC 5Y↑ -36.71%
Beone Medicines net debt vs free cash flow
ONC Risk
Great
  • Debt / Equity↓ 0.5
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 8.2

Beone Medicines stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗